Cue Biopharma shares surge 43.11% after-hours after reporting $21.9M Q4 collaboration revenue and 40% stake in ImmunoScape.

Cue Biopharma surged 43.11% in after-hours trading following the release of its Q4 2025 financial results and business highlights. The company reported $21.9 million in Q4 collaboration revenue, driven by its partnership with ImmunoScape, and secured $9.5 million of a $15 million upfront payment from the collaboration. Additionally, Cue Biopharma ended 2025 with $27.1 million in cash and a 40% equity stake in ImmunoScape, signaling improved financial flexibility. The stock also benefited from a Q4 earnings beat of $0.01 per share, exceeding the $0.10 loss estimate by 110%, and positive business developments, including progress on its lead autoimmune candidate CUE-401. These results underscored the company’s strategic momentum in advancing its Immuno-STAT platform and addressing unmet needs in autoimmune disease treatment, driving investor optimism in the after-hours session.